ADMA logo

ADMA Biologics, Inc.

ADMA

ADMA: ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.

more

Show ADMA Financials

All
Government
Consumer Interest
SEC Filings
ESG/Other

Recent trades of ADMA by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by ADMA's directors and management

Government lobbying spending instances

  • $10,000 Jul 19, 2023 Issue: Defense
  • $10,000 Apr 17, 2023 Issue: Defense
  • $10,000 Jan 18, 2023 Issue: Defense
  • $10,000 Oct 18, 2022 Issue: Defense
  • $10,000 Jul 14, 2022 Issue: Defense
  • $10,000 Apr 18, 2022 Issue: Defense
  • $10,000 Jan 18, 2022 Issue: Defense
  • $10,000 Oct 19, 2021 Issue: Health Issues Defense
  • $10,000 Apr 19, 2021 Issue: Health Issues Defense
U.S. Patents

New patents grants

  • Patent Title: Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection Aug. 10, 2021
  • Patent Title: Compositions and methods for the treatment of immunodeficiency Jun. 16, 2020
  • Patent Title: Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection Apr. 16, 2019
  • Patent Title: Compositions and methods for the treatment of immunodeficiency May. 15, 2018
  • Patent Title: Compositions and methods for the treatment of immunodeficiency Nov. 14, 2017
  • Patent Title: Compositions and methods for the treatment of immunodeficiency Jul. 25, 2017
  • Patent Title: Compositions and methods for the treatment of immunodeficiency Aug. 18, 2015
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of ADMA in WallStreetBets Daily Discussion

ADMA News

Recent insights relating to ADMA

CNBC Recommendations

Recent picks made for ADMA stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ADMA

Corporate Flights

Flights by private jets registered to ADMA